APOC3: Triglycerides do matter

Global Cardiology Science and Practice

Volumn 2014, Issue 3, 2014, Pages

  Hassan, Mohamed ^a,b  

^a Magdi Yacoub Heart Founda tion   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; TRIACYLGLYCEROL;

APOC3 GENE; ARTICLE; EXON; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; PROTEIN BLOOD LEVEL; RISK REDUCTION; SEQUENCE ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84991991316     PISSN: None     EISSN: 23057823     Source Type: Journal    
DOI: 10.5339/gcsp.2014.38     Document Type: Article

References (16)

1. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: A scientific statement from the american heart association. Circulation 2011;123(20]: 2292s333.
2. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease. Circulation 2007;115(4]: 450s8.
3. Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N. Engl. J. Med. 1993;328(17]: 1220s5.
4. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, lowSdensity lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am. J. Med. 1993;94(4]: 350s6.
5. Greene DJ, Skeggs JW, Morton RE. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SRs BI). J. Biol. Chem. 2001;276(7): 4804-11.
6. Norata GD, Grigore L, Raselli S, et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: Molecular mechanisms and gene expression studies. Atherosclerosis 2007;193(2): 321-7.
7. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 2006;113(5): 691-700.
8. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008;322(5908): 1702s5.
9. Crosby J, Peloso GM, Auer PL, et al. Losssofsfunction mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 2014;371(1): 22s31.
10. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management. lancet. Diabetes Endocrinol. 2014;2(8): 655s666.
11. J0rgensen AB, FrikkesSchmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Losssofsfunction mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 2014;371(1): 32s41.
12. Varbo A, Benn M, TybjaergsHansen A, J0rgensen AB, FrikkesSchmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 2013;61(4): 427s36.
13. Auwerx J, Schoonjans K, Fruchart JC, Staels B. Transcriptional control of triglyceride metabolism: Fibrates and fatty acids change the expression of the LPL and apo CII genes by activating the nuclear receptor PPAR. Atherosclerosis 1996;124 Suppl: S297.
14. Ooi EMM, Barrett PHR, Chan DC, Watts GF. Apolipoprotein CII: Understanding an emerging cardiovascular risk factor. Clin. Sci. (Lond). 2008;114(10): 611s24.
15. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 2013;45(11): 1345s52.
16. Graham MJ, Lee RG, Bell TA, et al. Antisense oligonucleotide inhibition of apolipoprotein CsIII reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 2013;112(11): 1479s90.